BetterLife Pharma Inc. News Releases

BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer

Wed, 19 Aug 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced the appointment of Mahan Chehrenama, DO, as Chief Medical Officer. Dr. Chehrenama will lead clinical development for BETR-001, the Company's non-hallucinogenic neuroplastogen advancing toward an Investigational New Drug (IND) application for...

BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism

Mon, 13 Jul 2026 08:00:00 -0400

Fully non-hallucinogenic, oral, non-scheduled 5-HT2A neuroplastogen differentiates BETR-001 from every other 5-HT2A agonist program; depression and other psychiatric disorders retained as optional future indications Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), today announced the prioritization of its lead clinical-stage asset, BETR-001, to pursue migraine and other primary headache...

BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee

Thu, 09 Jul 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of John W. LaRocca, Esq. to its Board of Directors. Mr. LaRocca will also serve as a member of the Company's Audit Committee.Mr. LaRocca is a three-decade biopharmaceutical industry executive...

BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1

Mon, 06 Jul 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Nucro-Technics Inc. ("Nucro") to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program.BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is a potent neuroplastogen and an agonist of the...

BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1

Thu, 25 Jun 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Syner-G BioPharma Group ("Syner-G") to oversee GMP manufacturing of BETR-001 for its planned IND and Phase 1 program.BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is active against neuroreceptors involved in migraines and cluster...

BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing

Mon, 22 Jun 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - June 22, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") today announced it has closed a CAD $2,000,000 convertible debenture financing ("Debenture" or "Financing"). The Debenture will fund the remaining IND-enabling work on the Company's lead candidate, BETR-001, as BetterLife sharpens its focus on neurological pain indications, with an initial emphasis on cluster headache and migraine.The...

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

Wed, 13 May 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director. At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in...

BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco

Tue, 06 Jan 2026 08:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatment of neurological disorders, today announced that it will be participating in the YAFO Capital Access Asia 2025 Partnering Forum, held in San Francisco, California,...

BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital

Thu, 11 Dec 2025 08:00:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), is pleased to announce it has signed an engagement agreement with Shanghai-based YAFO Capital ("YAFO"), as its exclusive advisor to seek strategic partnerships for development of BETR-001...